Clinical Trial Update: Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib with or without gemcitabine in advanced, unresectable kidney cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-13